Abstract
A topological index, which is a number, is connected to a graph. It is often used in chemometrics, biomedicine, and bioinformatics to anticipate various physicochemical properties and biological activities of compounds. The purpose of this article is to encourage original research focused on topological graph indices for the drugs azacitidine, decitabine, and guadecitabine as well as an investigation of the genesis of symmetry in actual networks. Symmetry is a universal phenomenon that applies nature's conservation rules to complicated systems. Although symmetry is a ubiquitous structural characteristic of complex networks, it has only been seldom examined in real-world networks. The (M)-polynomial, one of these polynomials, is used to create a number of degree-based topological coindices. Patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia who are not candidates for intense regimens, such as induction chemotherapy, are treated with these hypomethylating drugs. Examples of these drugs are decitabine (5-aza-20-deoxycytidine), guadecitabine, and azacitidine. The (M)-polynomial is used in this study to construct a variety of coindices for the three brief medicines that are suggested. New cancer therapies could be developed using indice knowledge, specifically the first Zagreb index, second Zagreb index, F-index, reformulated Zagreb index, modified Zagreb, symmetric division index, inverse sum index, harmonic index, and augmented Zagreb index for the drugs azacitidine, decitabine, and guadecitabine.